These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37256275)

  • 41. Hidradenitis suppurativa in the pediatric population.
    Liy-Wong C; Pope E; Lara-Corrales I
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S36-41. PubMed ID: 26470613
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic Drug Monitoring in Patients with Suboptimal Response to Adalimumab for Hidradenitis Suppurativa: A Retrospective Case Series.
    Abdalla T; Mansour M; Bouazzi D; Lowes MA; Jemec GBE; Alavi A
    Am J Clin Dermatol; 2021 Mar; 22(2):275-283. PubMed ID: 33242185
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
    Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
    J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-α agents.
    Megna M; Bettoli V; Chimenti S; Chiricozzi A; Naldi L; Virgili A; Girolomoni G; Monfrecola G
    G Ital Dermatol Venereol; 2015 Dec; 150(6):731-9. PubMed ID: 26513043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of Hidradenitis Suppurativa Disease Course During Pregnancy and Postpartum.
    Lyons AB; Peacock A; McKenzie SA; Jacobsen G; Naik HB; Shi VY; Hamzavi IH; Hsiao JL
    JAMA Dermatol; 2020 Jun; 156(6):681-685. PubMed ID: 32347884
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy.
    Molinelli E; Diotallevi F; Simonetti O; Brisigotti V; Sapigni C; Radi G; Campanati A; Offidani A
    Dermatol Ther; 2020 Nov; 33(6):e14256. PubMed ID: 32860474
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A Randomized Controlled Trial in a real-world setting.
    Aarts P; van Huijstee JC; van der Zee HH; van Doorn MBA; van Straalen KR; Prens EP
    J Am Acad Dermatol; 2023 Oct; 89(4):677-684. PubMed ID: 37116615
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa.
    Romaní J; Vilarrasa E; Martorell A; Fuertes I; Ciudad C; Molina-Leyva A
    Dermatology; 2020; 236(1):21-24. PubMed ID: 31288233
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adalimumab efficacy is inversely correlated with body mass index (BMI) in hidradenitis suppurativa.
    Nosrati A; Torpey ME; Shokrian N; Ch'en PY; Andriano TM; Benesh G; Heibel HD; Hosgood HD; Campton KL; Cohen SR
    Int J Dermatol; 2023 Jun; 62(6):764-769. PubMed ID: 36582044
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased Doses of Adalimumab are Associated With Clinical Improvement of Hidradenitis Suppurativa.
    Williams J; Guzik C; Wadhera A; Naik H
    J Drugs Dermatol; 2023 Jun; 22(6):615-618. PubMed ID: 37276155
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Validation of the Hidradenitis Suppurativa Investigator Global Assessment: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.
    Garg A; Zema C; Ciaravino V; Rolleri R; Peterson L; Garcia L; Massaro T; Jemec GBE; Kirby JS; Thorlacius L; Ingram JR
    JAMA Dermatol; 2023 Jun; 159(6):606-612. PubMed ID: 37099284
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Retrospective Cohort Study on Patients with Hidradenitis Suppurativa.
    Seyed Jafari SM; Knüsel E; Cazzaniga S; Hunger RE
    Dermatology; 2018; 234(1-2):71-78. PubMed ID: 29758553
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Narrative Review and Update on Biologic and Small Molecule Drugs for Hidradenitis Suppurativa: An Entity With a Promising Future.
    Mansilla-Polo M; Escutia-Muñoz B; Botella-Estrada R
    Actas Dermosifiliogr; 2023 Oct; 114(9):T772-T783. PubMed ID: 37541580
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Narrative Review and Update on Biologic and Small Molecule Drugs for Hidradenitis Suppurativa: An Entity With a Promising Future.
    Mansilla-Polo M; Escutia-Muñoz B; Botella-Estrada R
    Actas Dermosifiliogr; 2023 Oct; 114(9):772-783. PubMed ID: 37211274
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
    Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L
    Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advances in biologic and small molecule therapies for hidradenitis suppurativa.
    Chen SX; Greif C; Gibson RS; Porter ML; Kimball AB
    Expert Opin Pharmacother; 2022 Jun; 23(8):959-978. PubMed ID: 35470765
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
    Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
    Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: Prospective study of 32 patients.
    Nazzaro G; Calzari P; Passoni E; Vaienti S; Moltrasio C; Barbareschi M; Muratori S; Veraldi S; Marzano AV
    Dermatol Ther; 2021 Jan; 34(1):e14706. PubMed ID: 33368976
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.
    Zouboulis CC; Hansen H; Caposiena Caro RD; Damiani G; Delorme I; Pascual JC; Reguiai Z; Trigoni A; Vilarrasa E; Alfageme Roldán F
    Dermatology; 2020; 236(1):25-30. PubMed ID: 31630144
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
    Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T
    Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.